Differentiating Scleroderma from other diseases: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 239: | Line 239: | ||
* Antiphospholipid antibody | * Antiphospholipid antibody | ||
* Anti-Ro52 | * Anti-Ro52 | ||
| style="background: #F5F5F5; padding: 5px;" |Decreased C3, C4 and CH50 | | style="background: #F5F5F5; padding: 5px;" | | ||
* Decreased C3, C4 and CH50 | |||
* Anemia | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 247: | Line 249: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Malar rash | * Malar (butterfly) rash | ||
* Arthritis | * Arthritis | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Polymyositis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Polymyositis | ||
| Line 272: | Line 273: | ||
* Elevated creatinine kinase | * Elevated creatinine kinase | ||
* Aldolase | * Aldolase | ||
* Anemia | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 301: | Line 303: | ||
* Anti-CCP antibody | * Anti-CCP antibody | ||
* Anti-Ro52 | * Anti-Ro52 | ||
| style="background: #F5F5F5; padding: 5px;" |Elevated ESR | | style="background: #F5F5F5; padding: 5px;" | | ||
* Elevated ESR | |||
* Anemia | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Revision as of 23:03, 19 April 2018
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Differentiating Scleroderma from other diseases On the Web |
|
American Roentgen Ray Society Images of Differentiating Scleroderma from other diseases |
|
Risk calculators and risk factors for Differentiating Scleroderma from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating X from other Diseases
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
- [Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
- As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Preferred Table
| Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptoms | Physical examination | |||||||||||||||||
| Lab Findings | Imaging | Histopathology | ||||||||||||||||
| Skin changes | Raynaud phenomenon | Dysphagia | Dyspnea | Edema (swelling) | Sclerodactyly | Telangiectasia | Impaired mobility | Autoantibodies | Blood indices | Nailfold video capillaroscopy | CT-scan | Imaging 3 | ||||||
| Scleroderma | Limited cutaneous systemic sclerosis (CREST syndrome) | Skin thickening (induration) | + | + | +/- | +/- | + | + |
|
Anemia | Nailfold microvascular changes | Chest CT showing evidence of pulmonary fibrosis | Nailfold microvascular changes | Interstitial lung disease / Pulmonary hypertension | ||||
| Diffuse cutaneous systemic sclerosis | Skin thickening (induration) | + | + | +/- | +/- | + | + | +/- |
|
Anemia | Nailfold microvascular changes | |||||||
| Systemic diseases | Scleredema
(Buschke's disease)[1] |
Skin thickening | - | - | - | + | - | - | + | - | - | - |
|
| ||||
| Scleromyxedema
(lichen myxedematosus) |
Fibroblast proliferation in the dermis | |||||||||||||||||
| Amyloidosis | ||||||||||||||||||
| Eosinophilic fasciitis | + | Eosinophilia (peripheral blood smear) | ||||||||||||||||
| Chronic graft-versus-host disease | ||||||||||||||||||
| Drug induced scleroderma | ||||||||||||||||||
| Scleroderma overlap syndromes[2][3][4] | Systemic lupus erythematosus | Skin thickening/ rash | + | + | +/- | +/- | + | + | +/- |
|
|
Inflammation at the dermal-epidermal junction |
| |||||
| Polymyositis | Skin thickening/ rash | + | + | +/- | +/- | + | + | +/- |
|
|
|
Symmetric proximal muscle weakness | ||||||
| Rheumatoid arthritis | Skin thickening/ rash | + | + | +/- | +/- | + | + | +/- |
|
|
Inflammation at the dermal-epidermal junction | Clinical findings that suggest rheumatoid arthritis (RA) but do not fulfill the ACR criteria for RA | ||||||
| Endocrine disorders | Diabetes mellitus (diabetic cheiroarthropathy) | |||||||||||||||||
| Myxedema due to hypothyroidism | ||||||||||||||||||
| POEMS syndrome | ||||||||||||||||||
| Renal diseases | Nephrogenic systemic fibrosis | |||||||||||||||||
References
- ↑ Rongioletti F, Kaiser F, Cinotti E, Metze D, Battistella M, Calzavara-Pinton PG, Damevska K, Girolomoni G, André J, Perrot JL, Kempf W, Cavelier-Balloy B (December 2015). "Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients". J Eur Acad Dermatol Venereol. 29 (12): 2399–404. doi:10.1111/jdv.13272. PMID 26304054.
- ↑ Satoh M, Chan EK, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (September 2007). "Clinical implication of autoantibodies in patients with systemic rheumatic diseases". Expert Rev Clin Immunol. 3 (5): 721–38. doi:10.1586/1744666X.3.5.721. PMID 20477023.
- ↑ Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, Genth E, Guenther C, Hein R, Henes J, Herich L, Herrgott I, Koetter I, Kreuter A, Krieg T, Kuhr K, Lorenz HM, Meier F, Melchers I, Mensing H, Mueller-Ladner U, Pfeiffer C, Riemekasten G, Sárdy M, Schmalzing M, Sunderkoetter C, Susok L, Tarner IH, Vaith P, Worm M, Wozel G, Zeidler G, Hunzelmann N (April 2015). "Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis". Ann. Rheum. Dis. 74 (4): 730–7. doi:10.1136/annrheumdis-2013-204487. PMC 4392314. PMID 24389298.
- ↑ Foocharoen C, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R (September 2016). "Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma". Int J Rheum Dis. 19 (9): 913–23. doi:10.1111/1756-185X.12884. PMID 27126733.